Urbana-Champaign, Illinois – The Speech Accessibility Project is now recruiting U.S. and Puerto Rican adults with cerebral palsy. Those interested can sign up online. Funded by Big Tech companies Amazon, Apple, Google, Meta, and Microsoft, the University of Illinois Urbana-Champaign aims to train voice recognition technologies to understand people with diverse...
Latest News
CAMBRIDGE, Mass. – Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a collaboration with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson...
CAMBRIDGE, Mass. – Voyager Therapeutics, Inc. (Nasdaq: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced the U.S. Food and Drug Administration (FDA) has removed its clinical hold on the company’s Investigational New Drug (IND) application for VY-HTT01, a gene therapy candidate for the...
LEXINGTON, Mass. — Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy program...
Cambridge, England – Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular haemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). Voydeya is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care Ultomiris (ravulizumab) or Soliris...
WILMINGTON, Del. — AstraZeneca Pharmaceuticals LP and Ionis’ WAINUA™ (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, commonly referred to as hATTR-PN or ATTRv-PN. WAINUA is the only approved medicine for the treatment of ATTRv-PN that can be self-administered...
Farzana Nisha was about to lose her patience. She could not wait for the three-hour heart operation to end so she could see her two-year-old son. Fear overcame her after three hours and there seemed to be no end in sight to the surgery. Her son Rishab Prakash had a...
Chloe Bush is an adorable two year old that I visit and read to through a non-profit here in town called Circle of Hope. She has a terminal disease that is the #1 genetic killer of children under two. Chloe has surpassed that scary birthday but is still terribly ill...
Melbourne, Australia – Researchers from Melbourne-based medical research institute, WEHI, have unravelled how mutations in a gene can lead to an incurable neurodevelopmental disorder that causes abnormal brain development in newborns and infants. The study is the first to prove that a protein called Trabid helps control neuronal development, and that mutations...
SAN DIEGO, Calif. – Accelerated aging was more common in recent birth cohorts and was associated with increased incidence of early-onset solid tumors, according to research presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5-10. “Multiple cancer types are becoming increasingly common among younger...